1,328 results match your criteria Bacterial Overgrowth Syndrome


Lipocalin 2 deficiency-induced gut microbia dysbiosis evokes metabolic syndrome in aged mice.

Physiol Genomics 2020 Jul 6. Epub 2020 Jul 6.

Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, United States.

Lipocalin 2 (Lcn2) is a multifunctional innate immune protein that limits microbial overgrowth. Our previous study has demonstrated that the gut microbiota directly induces intestinal Lcn2 production, and Lcn2 deficient (Lcn2) mice exhibit gut dysbiosis. Coincidentally, gut dysbiosis is associated with metabolic syndrome pathogenesis and elevated Lcn2 levels has been considered a potential clinical biomarker of metabolic syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/physiolgenomics.00118.2019DOI Listing

[Changes in gut microbiota with bronchial asthma].

Ter Arkh 2020 Apr 27;92(3):56-60. Epub 2020 Apr 27.

Sechenov First Moscow State Medical University (Sechenov University).

Aim: To study the intestinal microbiota changes in patients with bronchial asthma (BA).

Materials And Methods: 40 patients and 15 healthy individuals were included for the study. The microbiota study in feces samples was performed by sequencing the 16SpRNA gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2020.03.000554DOI Listing

[Chronic pancreatitis with IBS-like syndrome: approach to therapy].

Ter Arkh 2020 Apr 27;92(2):61-66. Epub 2020 Apr 27.

Sechenov First Moscow State Medical University (Sechenov University).

Aim: To determine approaches of the exacerbations treatment of chronic pancreatitis (CP) with IBS (irritable bowel syndrome)-like syndrome.

Materials And Methods: 312 patients with exacerbation of CP were observed and received standard therapy: antispasmodics, enzymes, proton pump inhibitors. 85 (27. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2020.02.000518DOI Listing

[Evaluation of the effectiveness of differentiated therapy of non-alcoholic fatty liver disease].

Ter Arkh 2020 Apr 27;92(2):29-33. Epub 2020 Apr 27.

Izhevsk State Medical Academy.

Aim: Study of the effectiveness of differentiated therapy of non-alcoholic fatty liver disease taking into account the clinical and pathogenetic features of its course.

Materials And Methods: 168 patients with non-alcoholic fatty liver disease were examined, 108 of them were women and 60 men aged from 30 to 70 years. For treatment, depending on the characteristics of the course of the disease, 3 groups of patients were formed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2020.02.000400DOI Listing

[Association of food patterns with different forms of small intestinal bacterial overgroth syndrome and treatment efficacy].

Ter Arkh 2019 Oct 15;91(10):82-90. Epub 2019 Oct 15.

Federal Research Centre of Nutrition and Biotechnology.

Aim: To assess food patterns in patients with different types of SIBO and their impact onto the course and treatment outcomes.

Materials And Methods: The data of 988 patients who signed informed consent surved as a source data. On the basis of lactulose breath test (LBT; GastroCH4eck, Bedfont, UK), the patients were selected into one of the studied groups: SIBO-H2, SIBO-CH4, SIBO-CH4-H2 and control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.10.000496DOI Listing
October 2019

[Non - alcoholic fatty liver disease and enteral insufficiency: comorbidity of their development].

Ter Arkh 2019 Dec 15;91(12):84-89. Epub 2019 Dec 15.

Izhevsk State Medical Academy.

The article reflects current literature data on the epidemiology and risk factors of non - alcoholic fatty liver disease. An important aspect is the description of the modern views of combined lesions of the hepatobiliary tract and small intestine. Disorders of the intestinal microbiota play a special role in the development of non - alcoholic fatty liver disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.12.000134DOI Listing
December 2019

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.

BMC Gastroenterol 2020 Jun 12;20(1):187. Epub 2020 Jun 12.

Department of Gastroenterology and Hepatology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.

Background: Gut microbiota alterations including small intestinal bacterial overgrowth (SIBO) might play a role in pathogenesis of irritable bowel syndrome (IBS). Rifaximin could effectively and safely improve IBS symptoms. The aim of this study was to investigate the effect of rifaximin on Gastrointestinal (GI) symptoms, quality of life (QOL) and SIBO eradication in Chinese IBS-D patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12876-020-01336-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291629PMC

Pneumatosis intestinalis in COVID-19.

BMJ Open Gastroenterol 2020 06;7(1)

Medicina Interna, Azienda USL Toscana centro, Ospedale Santa Maria Annunziata, Firenze, Italy.

Introduction: COVID-19 is a respiratory illness due to novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), described in December 2019 in Wuhan (China) and rapidly evolved into a pandemic. Gastrointestinal (GI) tract can also be involved.

Case Presentation: A 44-year-old man was hospitalised for COVID-19-associated pneumonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjgast-2020-000434DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287500PMC

The importance of lactose intolerance in individuals with gastrointestinal symptoms.

Rev Gastroenterol Mex 2020 May 29. Epub 2020 May 29.

Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.

Lactose intolerance is a condition with an elevated prevalence worldwide, especially in Latin American, Asian, and African countries. The aim of the present narrative review was to highlight the importance of accurately diagnosing lactose intolerance to prevent self-diagnosis that results in the unnecessary elimination of milk and dairy products from the diet and the consequent deprivation of nutrients that could be essential at certain stages of life. The pathophysiologic mechanism of deficient lactose absorption in the intestine can be primary, secondary to other enteropathies, or coexistent with other intestinal diseases with similar symptoms, such as irritable bowel syndrome, bacterial overgrowth syndrome, or celiac disease, causing confusion in relation to diagnosis and treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rgmx.2020.03.002DOI Listing

Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.

Curr Microbiol 2020 May 29. Epub 2020 May 29.

Department of Surgical Oncology, Medical University of Gdansk, Mariana Smoluchowskiego 17, 80-214, Gdańsk, Poland.

The yeast Saccharomyces boulardii CNCM I-745 is a unique, non-bacterial microorganism classified as a probiotic agent. In this review article, at first, we briefly summarized the mechanisms responsible for its probiotic properties, e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00284-020-02053-9DOI Listing

Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.

Pharmacol Res 2020 May 26;159:104936. Epub 2020 May 26.

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. Electronic address:

Objective: Rifaximin for treating diarrhea-predominant irritable bowel syndrome (IBS-D) by regulating intestinal microbiota has been studied and recommended. In this study, we tried to investigate the effect of rifaximin on different components of intestinal microbiota and explore which component of gut microbiota can predict the efficacy of rifaximin in IBS-D.

Methods: Healthy controls (HC) and IBS-D patients meeting the Rome III criteria were recruited, and IBS-D patients were orally administered 400 mg rifaximin three times daily for 2 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2020.104936DOI Listing
May 2020
4.408 Impact Factor

The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders.

Int J Mol Sci 2020 May 16;21(10). Epub 2020 May 16.

Section of Gastroenterology, Department of Emergency and Organ Transplantation, University "Aldo Moro" of Bari, 70124 Bari, Italy.

Small intestinal bacterial overgrowth (SIBO) is a condition hallmarked by an increase in the concentration of colonic-type bacteria in the small bowel. Watery diarrhea, bloating, abdominal pain and distension are the most common clinical manifestations. Additionally, malnutrition and vitamin (B12, D, A, and E) as well as minerals (iron and calcium) deficiency may be present. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21103531DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279035PMC

König's Syndrome After Roux-en-Y Gastric Bypass: Candy Cane Twist.

Obes Surg 2020 Aug;30(8):3251-3252

Department of General and Digestive Surgery, Bariatric Surgery Unit, Poissy Saint Germain-en-laye, Saint Germain-en-laye, France.

Background: A König's syndrome is referred to abdominal pain in relation to meals with constipation alternated with diarrhea, meteorism, and abdominal distension. A postoperative long-term complication after Roux-en-Y gastric bypass could be the appearance of chronic abdominal pain associated with vomiting, dysphagia, and nausea.

Case Report: A 43-year-old female patient was submitted for a Roux-en-Y gastric bypass for morbid obesity with an initial body mass index (BMI) of 36 kg/m (weight 100 kg, height 168 cm). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11695-020-04563-8DOI Listing
August 2020
3.747 Impact Factor

Intestinal failure-associated liver disease (IFALD): insights into pathogenesis and advances in management.

Hepatol Int 2020 May 30;14(3):305-316. Epub 2020 Apr 30.

Section of Pediatric Gastroenterology, Hepatology and Nutrition and the Digestive Health Institute, Pediatric Liver Center, Colorado Clinical and Translational Sciences Institute, University of Colorado School of Medicine and Children's Hospital Colorado, 13123 E. 16th Ave., Box B290, Aurora, CO, 80045, USA.

Premature infants and children with intestinal failure (IF) or short bowel syndrome are susceptible to intestinal failure-associated liver disease (IFALD, previously referred to as parenteral nutrition-associated liver disease, or PNALD). IFALD in children is characterized by progressive cholestasis and biliary fibrosis, and steatohepatitis in adults, and is seen in individuals dependent upon prolonged administration of PN. Many factors have been proposed as contributing to the pathogenesis of IFALD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-020-10048-8DOI Listing

Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.

Indian J Gastroenterol 2020 Feb;39(1):9-21

Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, 226 014, India.

Evidence accumulates to implicate a role for the gut microbiota in non-alcoholic fatty liver disease (NAFLD)-a disorder that has reached almost epidemic proportions around the globe. For some time a disturbance in the gut microbiome, small intestinal bacterial overgrowth (SIBO), has been described among patients with liver disease, in general, and in the development and progression of NAFLD to nonalcoholic steatohepatitis (NASH), decompensated liver disease and hepatocellular cancer (HCC), in particular. More recently and permitted by the advent of high-throughput sequencing and allied molecular techniques, a much more detailed analysis of gut microbiota in NAFLD and NASH has become possible. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12664-020-01027-wDOI Listing
February 2020

Evaluation of lactulose, lactose, and fructose breath testing in clinical practice: A focus on methane.

JGH Open 2020 Apr 20;4(2):198-205. Epub 2019 Aug 20.

Department of Medicine, Dunedin School of Medicine University of Otago Dunedin New Zealand.

Background And Aim: Breath testing (BT) is used to identify carbohydrate malabsorption and small intestine bacterial overgrowth. Measuring methane alongside hydrogen is advocated to reduce false-negative studies, but the variability of methane production is unknown. The aim of this study is to examine the effect of high methane production on hydrogen excretion after ingesting lactulose, fructose, or lactose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jgh3.12240DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144793PMC

Determining the association between fibromyalgia, the gut microbiome and its biomarkers: A systematic review.

BMC Musculoskelet Disord 2020 Mar 20;21(1):181. Epub 2020 Mar 20.

Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia.

Background: The association between fibromyalgia and irritable bowel syndrome is well-established. Alterations in the composition and diversity of the gut microbiome in irritable bowel syndrome have been reported, however, this association is poorly understood in fibromyalgia. Our aim was to summarise the research reporting on the gastrointestinal microbiome and its biomarkers in people with fibromyalgia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12891-020-03201-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083062PMC

Factors Related to the Development of Small-Bowel Bacterial Overgrowth in Pediatric Intestinal Failure: A Retrospective Cohort Study.

JPEN J Parenter Enteral Nutr 2020 Mar 13. Epub 2020 Mar 13.

Transplant and Regenerative Medicine Centre, Toronto, Canada.

Background: Small bowel bacterial overgrowth (SBBO) is a challenge in the management of pediatric intestinal failure (PIF). Our goal was to determine the proportion of patients treated for SBBO and factors related to its development.

Methods: We completed a retrospective analysis of PIF patients referred between 2008 and 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jpen.1809DOI Listing

Association between interstitial cells of Cajal and anti-vinculin antibody in human stomach.

Korean J Physiol Pharmacol 2020 Mar 20;24(2):185-191. Epub 2020 Feb 20.

Kangwon National University Institute of Medical Science, Chuncheon 24289, Korea.

Interstitial cells of Cajal (ICC) are known as the pacemaker cells of gastrointestinal tract, and it has been reported that acute gastroenteritis induces intestinal dysmotility through antibody to vinculin, a cytoskeletal protein in gut, resulting in small intestinal bacterial overgrowth, so that anti-vinculin antibody can be used as a biomarker for irritable bowel syndrome. This study aimed to determine correlation between serum anti-vinculin antibody and ICC density in human stomach. Gastric specimens from 45 patients with gastric cancer who received gastric surgery at Kangwon National University Hospital from 2013 to 2017 were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4196/kjpp.2020.24.2.185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043993PMC

Rational investigations in irritable bowel syndrome.

Frontline Gastroenterol 2020 Mar 6;11(2):140-147. Epub 2019 Jun 6.

Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder which accounts for a substantial proportion of a gastroenterologist's time in the outpatient clinic. However, there is variability in approaches to diagnosis and investigation between physicians, dependent on expertise. Many patients express disappointment over the lack of a patient-centred approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/flgastro-2019-101211DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043084PMC

Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.

Int J Mol Sci 2020 Feb 23;21(4). Epub 2020 Feb 23.

Genome Analysis Center, Yamanashi Central Hospital, Yamanashi 400-8506, Japan.

Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), causes hepatic fibrosis, cirrhosis and hepatocellular carcinoma (HCC). The patatin-like phospholipase-3 (PNPLA3) I148M sequence variant is one of the strongest genetic determinants of NAFLD/NASH. PNPLA3 is an independent risk factor for HCC among patients with NASH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21041525DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073210PMC
February 2020

Clinical and histological recovery of non-thymoma-associated exfoliative dermatitis in a cat treated with ciclosporin A.

JFMS Open Rep 2020 Jan-Jun;6(1):2055116920902307. Epub 2020 Feb 11.

Department of Clinical Sciences, Université de Toulouse, ENVT, Toulouse, France; UDEAR, Université de Toulouse, INSERM, ENVT, Toulouse, France.

Case Summary: A 6-year-old neutered female European Shorthair cat was referred for chronic, moderately pruritic, alopecic and exfoliative dermatosis that was unresponsive to antiparasitic, antibiotic or steroidal anti-inflammatory drugs. The cat presented with truncular alopecia and numerous whitish adherent scales covering the whole body. Differential diagnoses included sebaceous adenitis, dermatophytosis, demodicosis, exfoliative dermatitis associated or not with thymoma, drug reaction, feline immunodeficiency virus- or feline leukaemia virus-associated dermatoses, epitheliotropic T-cell lymphoma, and yeasts and/or bacterial overgrowth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2055116920902307DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013115PMC
February 2020

[The role of dietary diversity in the formation of syndrome intestinal bacterial overgrowth].

Vopr Pitan 2020;89(1):54-63. Epub 2020 Jan 24.

Federal Research Centre of Nutrition, Biotechnology and Food Safety, 115446, Moscow, Russian Federation.

Small intestinal bacterial overgrowth (SIBO) is a widespread disease characterized by a significant decrease of the quality of life. Antibiotic treatment of SIBO is usually effective, however, the recurrence rate is high. Microbiota is dependent on dietary pattern of the patient and specific nutrients, therefore the diversity of dietary patterns may be one of the major factor promoting SIBO or its relapses after treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24411/0042-8833-2020-10006DOI Listing
January 2020

A comparison of small bowel and fecal microbiota in children with short bowel syndrome.

J Pediatr Surg 2020 May 1;55(5):878-882. Epub 2020 Feb 1.

Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA; Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Background: Babies with short bowel syndrome (SBS) have small intestinal microbial disturbances that impact gut function. Characterizing the small bowel microbiota is challenging, and the utility of sampling stool is unclear. This study compares the microbiota from fecal samples and the small bowel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpedsurg.2020.01.032DOI Listing

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review.

Therap Adv Gastroenterol 2020 23;13:1756284819897531. Epub 2020 Jan 23.

Division of Epidemiology, Human Genetics and Environmental Sciences and Center for Infectious Diseases, University of Texas School of Public Health, Houston, TX, USA.

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with a multifactorial pathophysiology. The gut microbiota differs between patients with IBS and healthy individuals. After a bout of acute gastroenteritis, postinfection IBS may result in up to approximately 10% of those affected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756284819897531DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984424PMC
January 2020

Microbiome and Its Role in Irritable Bowel Syndrome.

Dig Dis Sci 2020 Mar;65(3):829-839

Division of Gastroenterology, Beth Israel Deaconess Hospital, Boston, MA, USA.

Irritable bowel syndrome (IBS) is an extremely common and often very debilitating chronic functional gastrointestinal disorder. Despite its prevalence, significant associated healthcare costs, and quality-of-life issues for affected individuals, our understanding of its etiology remained limited. However, it is now evident that microbial factors play key roles in IBS pathophysiology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-020-06109-5DOI Listing

ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.

Am J Gastroenterol 2020 02;115(2):165-178

Division of Gastroenterology/Hepatology, Augusta University, Augusta, Georgia, USA.

Small intestinal bacterial overgrowth is defined as the presence of excessive numbers of bacteria in the small bowel, causing gastrointestinal symptoms. This guideline statement evaluates criteria for diagnosis, defines the optimal methods for diagnostic testing, and summarizes treatment options for small intestinal bacterial overgrowth. This guideline provides an evidence-based evaluation of the literature through the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/ajg.0000000000000501DOI Listing
February 2020

Paradoxical Elevation of Both Serum B12 and Methylmalonic Acid Levels in Assessing B12 Status in Children With Short-Bowel Syndrome.

JPEN J Parenter Enteral Nutr 2020 Jan 27. Epub 2020 Jan 27.

Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York, USA.

Background: Measurement of vitamin B (B12) levels is routinely used to monitor B12 sufficiency. However, its accuracy may not be reliable in patients with short-bowel syndrome (SBS). The presence of elevated methylmalonic acid (MMA) levels can also be used as a marker for B12 deficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jpen.1764DOI Listing
January 2020

Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome.

Sci Rep 2020 01 17;10(1):593. Epub 2020 Jan 17.

Inst. of Medicine, University of Gothenburg, Gothenburg, Sweden.

Altered bacterial composition and small intestinal bacterial overgrowth (SIBO) may be associated with irritable bowel syndrome (IBS). This study aimed to determine the fecal and mucosa-associated bacterial composition along the gastrointestinal (GI) tract and to assess SIBO in IBS. Bacterial composition of feces, and mucosa of the duodenum and sigmoid colon was determined by 16S rRNA-amplicon-sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-57468-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969101PMC
January 2020

Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies.

Am J Gastroenterol 2020 02;115(2):190-201

Faculty of Medicine & Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia.

Introduction: We conducted a systematic review and meta-analysis to compare the prevalence of small intestinal bacterial overgrowth (SIBO) in patients with irritable bowel syndrome (IBS) and controls.

Methods: Electronic databases were searched up to December 2018 for studies reporting SIBO prevalence in patients with IBS. Prevalence rates, odds ratios (ORs), and 95% confidence intervals (CIs) of SIBO in patients with IBS and controls were calculated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/ajg.0000000000000504DOI Listing
February 2020

Management of afferent loop syndrome after Roux-en-Y subtotal gastrectomy and choledocolithiasis with recurrent cholangitis.

BMJ Case Rep 2020 Jan 5;13(1). Epub 2020 Jan 5.

General Surgery, Hospital and University Centre of Coimbra, Coimbra, Portugal.

Afferent loop syndrome is a rare complication after gastrectomy with Billroth II or Roux-en-Y reconstruction, caused by an obstruction in the proximal loop. The biliary stasis and bacterial overgrowth secondary to this obstruction can lead to repeated episodes of acute cholangitis. We present the case of a male patient who had previously undergone gastrectomy with Roux-en-Y reconstruction and later experienced multiple episodes of acute cholangitis secondary to choledocolithiasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-232498DOI Listing
January 2020

Association of Intestinal Disorders with Parkinson's Disease and Alzheimer's Disease: A Systematic Review and Meta-Analysis.

ACS Chem Neurosci 2020 02 8;11(3):395-405. Epub 2020 Jan 8.

Department of Biology , Hong Kong Baptist University , Kowloon Tong 999077 , Hong Kong SAR, China.

Parkinson's disease (PD) and Alzheimer's disease (AD) are the most common neurodegenerative disorders, with an overall global incidence of 40 million. Many studies have revealed the association of intestinal disorders and bacterial infections with PD, but few studies have found such a relationship with AD. In this meta-analysis, related articles published up to September 2018 were searched in PubMed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschemneuro.9b00607DOI Listing
February 2020

Effect of eradicating hydrogen-forming small intestinal bacterial overgrowth with rifaximin on body weight change.

Medicine (Baltimore) 2019 Dec;98(51):e18396

Department of Family Practice and Community Health, Ajou University School of Medicine, Suwon.

Hydrogen formed by small intestinal bacterial overgrowth in patients with non-constipated irritable bowel syndrome has an inverse relationship with obesity. However, the effect of eradicating small intestinal hydrogen-producing bacterial overgrowth on the body weight of these patients has not yet been reported. The aim of this study was to investigate body weight changes after eradicating small intestinal bacterial overgrowth with rifaximin treatment in patients with non-constipated irritable bowel syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000018396DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940060PMC
December 2019

Carbohydrate Intolerance and Disaccharidase Measurement - a Mini-Review.

Authors:
Matthew Burke

Clin Biochem Rev 2019 Nov;40(4):167-174

Chemical Pathology, Pathology Queensland, Herston, Qld 4029, Australia.

Carbohydrate intolerance is one of several syndromes and diseases which together are known as malabsorption syndromes. These include small intestinal bacterial overgrowth (SIBO), coeliac disease, intestinal lymphangiectasia, short bowel syndrome, tropical sprue and some inherited metabolic disorders such as galactosaemia and pyruvate kinase deficiency. Specifically, the malabsorption of sugars affects morbidity for millions of sufferers across the world. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.33176/AACB-19-00025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892707PMC
November 2019

Imaging Measurement of Whole Gut Transit Time in Paediatric and Adult Functional Gastrointestinal Disorders: A Systematic Review and Narrative Synthesis.

Diagnostics (Basel) 2019 Dec 13;9(4). Epub 2019 Dec 13.

Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham NG7 2UH, UK.

Background: functional gastrointestinal disorders (FGID) are common conditions in children and adults, often associated with abnormalities of whole gut transit. Currently, transit tests can be performed using several imaging methods, including tracking of radiopaque markers, gamma scintigraphy with the use of radioisotopes, magnetic tracking methods, tracking of movement of wireless motility capsules, and emerging magnetic resonance imaging (MRI) approaches.

Objectives: to review recent literature on diagnostic imaging techniques used to investigate whole gut transit in FGIDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/diagnostics9040221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963386PMC
December 2019

Review of the management of diarrhea syndrome after a bariatric surgery.

Endocrinol Diabetes Nutr 2020 Jun - Jul;67(6):401-407. Epub 2019 Dec 13.

Unidad de Gastroenterología, Servicio de Aparato Digestivo, Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Barcelona, España.

Obesity is a prevalent health problem in our population. Bariatric surgery is the indicated treatment for severe cases. It is very effective (together with an adequate lifestyle modification) but it is also associated with frequent adverse events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.endinu.2019.09.013DOI Listing
December 2019

Increased fasting small-bowel water content in untreated coeliac disease and scleroderma as assessed by magnetic resonance imaging.

United European Gastroenterol J 2019 12 21;7(10):1353-1360. Epub 2019 Jun 21.

Nottingham Digestive Diseases Centre, University of Nottingham and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK.

Background And Aims: The regular overnight migrating motor complex (MMC) ensures that the normal fasting small-bowel water content (SBWC) is minimised. We have applied our recently validated non-invasive magnetic resonance technique to assess SBWC in newly diagnosed coeliac disease (CD), scleroderma (SCD) and irritable bowel syndrome (IBS), conditions possibly associated with small intestinal bacterial overgrowth (SIBO).

Methods: A total of 20 CD and 15 SCD patients with gastrointestinal symptoms were compared to 20 healthy volunteers (HV) and 26 IBS with diarrhoea (IBS-D) patients, as previously reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050640619860372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894006PMC
December 2019

Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis?

Turk J Gastroenterol 2019 Nov;30(11):964-975

Department of Gastroenterology and Hepatology, Sechenov University, Moscow, Russia.

Background/aims: Small intestinal bacterial overgrowth (SIBO) and hemodynamic changes are common in cirrhosis. We wanted to examine our hypothesis whether SIBO leads to hemodynamic changes in cirrhosis.

Materials And Methods: A total of 50 patients with cirrhosis and 15 healthy controls were enrolled in a pilot prospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/tjg.2019.18551DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883995PMC
November 2019

Small intestinal bacterial overgrowth is associated with Diarrhea-predominant irritable bowel syndrome by increasing mainly abundance.

Scand J Gastroenterol 2019 Dec 25;54(12):1419-1425. Epub 2019 Nov 25.

Department of Gastroenterology, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, People's Republic of China.

Diarrhea-predominant irritable bowel syndrome (IBS-D) is the main subtype of IBS, a chronic functional gastrointestinal disorder. Small intestinal bacterial overgrowth (SIBO), which is characterized by dysbiosis of the bowel, causes gastrointestinal symptoms quite similar to IBS-D. However, whether SIBO correlates with IBS-D and its further mechanism remain unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00365521.2019.1694067DOI Listing
December 2019

Breath Test Gas Patterns in Inflammatory Bowel Disease with Concomitant Irritable Bowel Syndrome-Like Symptoms: A Controlled Large-Scale Database Linkage Analysis.

Dig Dis Sci 2019 Nov 21. Epub 2019 Nov 21.

Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Introduction: Breath testing (BT) has gained interest for diagnosing small intestinal bacterial overgrowth (SIBO) in IBD patients with irritable bowel syndrome (IBS) overlap. We aim to characterize the rate of SIBO and BT gas patterns in IBD patients with IBS-like symptoms compared to non-IBD patients.

Methods: A database of 14,847 consecutive lactulose BTs was developed from patients with IBS-like symptoms between November 2005 and October 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-019-05967-yDOI Listing
November 2019

A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome.

J Gastroenterol Hepatol 2020 Jun 17;35(6):922-931. Epub 2019 Dec 17.

Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.

Background: Enteric microbiota is increasingly being recognized as an important factor in the pathogenesis of irritable bowel syndrome (IBS). The reported prevalence of small intestinal bacterial overgrowth (SIBO) in subjects with IBS is highly variable, and there is no consensus on the role of SIBO in different subtypes of IBS, and indications and methods of testing.

Methods: A comprehensive literature search was performed for studies applying tests for SIBO in subjects with IBS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.14938DOI Listing

[Features of nutrition pattern of patients with small intestinal bacterial overgrowth resistant to therapy].

Vopr Pitan 2019;88(5):31-38. Epub 2019 Sep 19.

Federal Research Centre of Nutrition, Biotechnology and Food Safety, Moscow, Russia.

Small intestinal bacterial overgrowth (SIBO) is a widespread disease characterized by a significant decrease in the quality of life. Antibiotic treatment with SIBO is not effective enough and the recurrence rate is high. Long-term dietary patterns can shift the composition of the microbiota. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24411/0042-8833-2019-10051DOI Listing

CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES - 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS - .

Endocr Pract 2019 Dec 4;25(12):1346-1359. Epub 2019 Nov 4.

The development of these updated clinical practice guidelines (CPGs) was commissioned by the American Association of Clinical Endocrinologists (AACE), The Obesity Society, American Society of Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists Boards of Directors in adherence with the AACE 2017 protocol for standardized production of CPGs, algorithms, and checklists. Each recommendation was evaluated and updated based on new evidence from 2013 to the present and subjective factors provided by experts. New or updated topics in this CPG include: contextualization in an adiposity-based chronic disease complications-centric model, nuance-based and algorithm/checklist-assisted clinical decision-making about procedure selection, novel bariatric procedures, enhanced recovery after bariatric surgery protocols, and logistical concerns (including cost factors) in the current health-care arena. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4158/GL-2019-0406DOI Listing
December 2019
1 Read

Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome.

J Gastroenterol Hepatol 2020 May 5;35(5):795-805. Epub 2019 Nov 5.

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Background And Aim: Small intestinal bacterial overgrowth (SIBO) has been proposed as an etiologic factor in irritable bowel syndrome, particularly the diarrhea-predominant subtype (IBS-D). We aimed to identify potential intestinal microbial pattern in IBS-D patients with SIBO.

Methods: Diarrhea-predominant irritable bowel syndrome patients fulfilling Rome III criteria were recruited and randomly divided into an exploratory cohort (57 cases) and a validation cohort (20 cases). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.14910DOI Listing
May 2020
1 Read
3.504 Impact Factor

ANALYSIS OF LACTOSE INTOLERANCE IN STUDENTS WITH SUGGESTIVE SYMPTOMS OF IRRITABLE BOWEL SYNDROME.

Arq Gastroenterol 2019 30;56(3):304-311. Epub 2019 Sep 30.

Faculdade de Medicina da Universidade Federal Do Vale do São Francisco, Paulo Afonso, BA, Brasil.

Background: Irritable bowel syndrome is a clinical condition presenting pain, distension and abdominal fullness, diarrhea, constipation, and other symptoms. It generates significant impacts on the quality of life of those affected. The pathophysiology is uncertain, but the role of various food types has been established in bowel sensitivity and its clinical manifestations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/S0004-2803.201900000-57DOI Listing
December 2019
1 Read

Small intestinal bacterial overgrowth in children with intestinal failure on home parenteral nutrition.

JGH Open 2019 Oct 4;3(5):394-399. Epub 2019 Apr 4.

Department of Gastroenterology and Clinical Nutrition The Royal Children's Hospital Melbourne Victoria Australia.

Background And Aim: Children with intestinal failure (IF) have abnormal intestinal anatomy, secretion, or motility, which impairs homeostatic mechanisms and can lead to small intestinal bacterial overgrowth (SIBO). We sought to describe clinical features at the time of clinically suspected SIBO by experienced clinicians in children with IF on home parenteral nutrition (PN), review specific challenges of diagnostic testing in this population, and describe potential new diagnostic surrogate markers.

Methods: A descriptive single-center retrospective chart review was performed during all episodes of clinically suspected SIBO over 33 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jgh3.12174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788370PMC
October 2019

Bariatric Surgery and Its Complications in Inflammatory Bowel Disease Patients.

Inflamm Bowel Dis 2019 Oct 18. Epub 2019 Oct 18.

Department of Gastroenterology, Hepatology & Nutrition, Center for Human Nutrition, Center for Gut Rehabilitation and Intestinal Transplantation, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Recent data have suggested that bariatric procedures, especially laparoscopic sleeve gastrectomy (SG), are safe and effective weight loss measures in patients with inflammatory bowel disease (IBD). But most of the studies have looked at short-term outcomes, and there is a general lack of awareness of underlying disease processes and baseline comorbidities in IBD patients undergoing bariatric procedures. Postbariatric issues in IBD patients including diarrhea from dumping syndrome, choleretic diarrhea, a high prevalence of small intestinal bacterial overgrowth, gastroesophageal reflux disease, Barrett's esophagus, stomal ulcerations, stenosis, and renal and gallstones can complicate the natural history of IBD. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ibdjournal/advance-article/doi/10.1
Publisher Site
http://dx.doi.org/10.1093/ibd/izz246DOI Listing
October 2019
5 Reads

Diagnostic Utility of Carbohydrate Breath Tests for SIBO, Fructose, and Lactose Intolerance.

Dig Dis Sci 2020 May 15;65(5):1405-1413. Epub 2019 Oct 15.

Division of Gastroenterology and Hepatology, Department of Medicine, Augusta University, 1120 15th Street, Augusta, GA, 30912, USA.

Background: Unexplained bloating, gas, and pain are common symptoms. If routine tests are negative, such patients are often labeled as irritable bowel syndrome.

Aims: To determine the diagnostic utility of breath tests that assess for small intestinal bacterial overgrowth (SIBO), fructose or lactose intolerance, and the predictive value of symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-019-05889-9DOI Listing
May 2020
2 Reads

DPP4 inhibitor reinforces cell junction proteins in mouse model of short bowel syndrome.

Pediatr Surg Int 2020 Jan 1;36(1):49-55. Epub 2019 Oct 1.

Department of Pediatric General and Urogenital Surgery, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Purpose: Bacterial overgrowth commonly occurs and favors bacterial translocation in short bowel syndrome (SBS). Glucagon-like peptide-2 (GLP-2) is effective for treating SBS, but is rapidly inactivated by dipeptidyl peptidase IV (DPP4). DPP4 inhibitor (DPP4I) is known to be effective for treating SBS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00383-019-04571-5DOI Listing
January 2020
1 Read

Is SIBO A Real Condition?

Authors:
Michael Ruscio

Altern Ther Health Med 2019 Sep;25(5):30-38

Context: Small intestinal bacterial overgrowth (SIBO) has gained popularity on the internet in addition to certain clinical and research circles. This interest has expanded awareness of important new dietary, nutraceutical, and pharmaceutical treatments in addition to laboratory evaluation assessment options. Concomitantly, there appears a loss of parsimony regarding how to use these tools resulting in an untenable degree of testing and treatment for this condition. Read More

View Article

Download full-text PDF

Source
September 2019
1 Read